Anika Therapeutics | ANIK - Ativo Circulante





Ativo Circulante Alterar Data
Abbott USD 25.51B 488M 2026-03
Agenus USD 95.28M 38.15M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.84B 665.36M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Halozyme Therapeutics USD 1B 177.83M 2026-03
Heron Therapeutics USD 228.98M 9.08M 2026-03
Insmed USD 1.61B 181.04M 2026-03
Integra LifeSciences USD 1.17B 12.47M 2026-03
Intrexon USD 23.72M 45.04M 2024-06
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Ligand Pharmaceuticals USD 865.42M 33.14M 2026-03
MacroGenics USD 182.52M 37.42M 2026-03
Merit Medical Systems USD 1.1B 61.62M 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.16B 789M 2026-03
Smith & Nephew USD 4.63B 169M 2025-12
Stryker USD 13.34B 1.42B 2026-03
Veracyte USD 522.17M 33.8M 2026-03
Xencor USD 482.85M 116.97M 2026-03
Zimmer Biomet Holdings USD 4.96B 157.4M 2026-03